Drug-Eluting stents offer no advantage for A-Fib patients

June 22, 2012
Drug-Eluting stents offer no advantage for A-Fib patients
Drug-eluting stents do not seem to offer advantages over bare-metal stents for patients with atrial fibrillation who undergo percutaneous coronary intervention with stent implantation, according to research published in the July 1 issue of The American Journal of Cardiology.

(HealthDay) -- Drug-eluting stents (DESs) do not seem to offer advantages over bare-metal stents (BMSs) for patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent implantation, according to research published in the July 1 issue of The American Journal of Cardiology.

Laurent Fauchier, M.D., Ph.D., of the Université François Rabelais in Tours, France, and colleagues compared the efficacy and safety of DESs with BMSs in 833 consecutive unselected patients with AF, seen from 2000 to 2010, who had undergone PCI with stent implantation.

Of the stents implanted, 81 percent were BMSs and 19 percent were DESs. During a median follow-up of 688 days, the researchers found that the incidence of all-cause mortality and of major adverse cardiac events (MACEs; death, acute myocardial infarction, target lesion revascularization) was similar between the two groups. The results remained similar after adjustment for confounders and age. Older age, implantation of stent during acute ST-segment elevation myocardial infarction, and stent diameter were significantly and independently associated with an increased risk of MACEs. DESs did not correlate with a higher risk of bleeding, and the ratio of serious events at follow-up was similar for DES and BMS implantation.

"In conclusion, in our cohort, systematic use of DESs does not seem to be justified in most patients with AF because it was not associated with any clear advantage compared to BMSs," the authors write.

Explore further: Comparison of anticoagulants for angioplasty show similar outcomes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Good long-term outcomes for drug-eluting stents

April 4, 2012

(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, or recurrent ...

Recommended for you

Amyloid-related heart failure now detectable with imaging test

August 24, 2016

A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study led by researchers at Columbia ...

Biomarkers may help better predict who will have a stroke

August 24, 2016

People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.